News | November 02, 2012

Mevion Medical Systems Continues Manufacturing Ramp up for Mevion S250 Proton Therapy System

A fifth proton accelerator enters manufacturing line at Mevion headquarters

Mevion S250 Proton Therapy

November 2, 2012 —  Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.

“The Mevion S250 has redefined the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to the level of modern radiation therapy,” said Scot Ackerman, medical director for First Coast Oncology. “Our Mission has been to provide the most advanced radiation treatment for our cancer patients, and the Mevion S250 will allow us to offer to our patients the full benefits of proton therapy.”

The Mevion S250 proton therapy system represents the latest innovation in proton therapy, providing the same precise, non-invasive treatment advantages and capabilities of larger proton therapy systems but with a significantly reduced footprint, improved reliability, high patient throughput, more advanced clinical systems and lower implementation and operational costs. Powered by a patented gantry-mounted TriNiobium Core accelerator, the Mevion S250 has a footprint only slightly larger than a conventional linear accelerator.

In addition to the construction at First Coast Oncology, the Mevion S250 is installed at Washington University, St. Louis, Mo., and is under installation at Robert Wood Johnson University Hospital, New Brunswick, N.J. and Oklahoma University. An additional site in Florida, MD Anderson Cancer Center in Orlando just broke ground in September 2012.

More than a dozen Mevion S250 proton therapy systems are slated to be installed in the United States including five NCI Designated Comprehensive Cancer Center, and six international projects. “The simple and modular design of the Mevion S250 supports a lean and fast manufacturing process. This is a first in proton therapy which traditionally has been limited by the enormous size and complexity of the device”, says Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. The Mevion S250 is the only proton therapy system designed and manufactured in the United States, and has recently received United States Food and Drug Administration (FDA) 510(k) clearance and CE certification enabling Mevion customers to treat patients.

For more information: www.Mevion.com

Related Content

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
IBA Announces First Patient Treated with Proteus PLUS in The Netherlands
News | Proton Therapy | January 25, 2018
January 25, 2018 –  IBA (Ion Beam Applications SA) has announced that the University Medical Center Groningen (UMCG)
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
Overlay Init